Neurology Specific Literature Search   
 
[home][thesaurus]
    

Enter your terms
above and click
the 'Search' button.
Showing articles 0 to 20 of 20

Filter Applied: fibrinolytic therapy,timing of administration (Click to remove)

Small Step or Giant Leap? Expanding the Acute Stroke Thrombolysis Window to 24 Hour
NEJM 391:273-275, Lee,V.H., 2024

Thrombolysis for Acute Ischemic Stroke in the Unwitnessed or Extended Therapeutic Time Window
Neurol 94:e1241-e1248, Tsivgoulis, G.,et al, 2020

Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018

And Why Not Thrombolysis in the Ambulance (At Least for Some)?
Neurol 87:214-219, Rosenberg, G. & Steiner, I., 2016

Effects of Golden Hour Thrombolysis
JAMA Neurol 72:25-30,9, Ebinger, M.,et al, 2015

Prehospital Thrombolysis in Acute Stroke
Neurol 80:163-168, Weber, J.,et al, 2013

Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013

Results of Intravenous Thrombolysis within 4.5 to 6 Hours and Updated Results within 3 to 4.5 Hours of Onset of Acute Ischemic Stroke Recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR)
JAMA Neurol 70:837-844, Ahmed, N.,et al, 2013

Thrombolysis of Basilar Artery Occlusion: Impact of Baseline Ischemia and Time
Ann Neurol 73:688-694, Strbian, D.,et al, 2013

The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial
Lancet 379: 2320, IST-3 collaborative group, 2012

Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis
Lancet 379: 2364-2372, Wardlaw, J.M.,et al, 2012

Remote Supervision of IV-tPA for Acute Ischemic Stroke by Telemedicine or Telephone Before Transfer to a Regional Stroke Center Is Feasible and Safe
Stroke 41:e18-e24, Pervez,M.,et al, 2010

Endovascular Treatment of Acute Ischemic Stroke May Be Safely Performed With No Time Window Limit in Appropriately Selected Patients
Stroke 41:1996-2000, Abou-Chebl,A.,et al, 2010

Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009

Thrombolysis with Alteplase 3-4.5 h After Ischaemic Stroke (SITS-ISTR): An Observational Study
Lancet 372:1303-1309, Wahlgren,N.,et al, 2008

Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke
NEJM 359:1317-1329,1393, Hacke,W.,et al, 2008

MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows
Stroke 38:2640-2645, Schellinger,P.D.,et al, 2007

An Expedited Code Stroke Protocol Is Feasible and Safe
Stroke 37:2935-2939,2863, Sattin,J.A.,et al, 2006

The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase
Stroke 36:66-73, Hacke,W.,et al, 2005

The Ethics of Thrombolytic Trials Beyond 3 (or 4.5) Hours: Randomized Controlled Trials Are Required to Change Clinical Practice
Stroke 40:1545, Donnan,G.A. &Davis,S.M., 2009



Showing articles 0 to 20 of 20